Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Edesa Biotech Inc

Current price
3.5 USD -0.12 USD (-3.31%)
Last closed 3.38 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 10 600 056 USD
Yield for 12 month +275.50 %
21.11.2021 - 28.11.2021

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. Address: 100 Spy Court, Markham, ON, Canada, L3R 5H6


WallStreet Target Price

36 USD

P/E ratio

Dividend Yield

0.28 %

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures EDSA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -9 532 970 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -44.92 %
PEG Ratio
Return On Equity TTM -96.18 %
Wall Street Target Price 36 USD
Revenue TTM 500 USD
Book Value 2.63 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -99.9 %
Dividend Yield 0.28 %
Gross Profit TTM 311 200 USD
Earnings Share -2.45 USD
Diluted Eps TTM -2.45 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics EDSA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EDSA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 0.28 %
Last Split Factor 1:7
Payout Ratio
Last Split Date 11.10.2023
Dividend Date 10.06.2019

Stock Valuation EDSA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 0.1716
Enterprise Value Revenue 128525.384
Price Sales TTM 120477.9295
Enterprise Value EBITDA -0.4406
Price Book MRQ 1.3424

Financials EDSA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators EDSA

For 52 weeks

2.46 USD 19.67 USD
50 Day MA 3.68 USD
Shares Short Prior Month 29 616
200 Day MA 6.03 USD
Short Ratio 0.66
Shares Short 23 234
Short Percent 0.92 %